High-risk strains of human papillomavirus (HPV)—ones that have been linked to anogenital and oral cancers—might also increase a woman’s risk for developing cardiovascular disease, research out of Seoul, South Korea, suggests.
Patients with chronic angina pectoris who experience incomplete revascularization after percutaneous coronary intervention (PCI) may fare better if they’re optimistic about their own recovery, according to a study published in the American Journal of Cardiology Feb. 7.
Cardiovascular diagnoses such as chest pain and atherosclerotic heart disease are key drivers of outpatient payments, which accounted for almost 57 percent of hospitals’ net patient revenue in 2017, according to data compiled by Definitive Healthcare.
Just half of Americans know the five common heart attack symptoms—even when presented with the symptoms as “yes” or “no” answers—based on 2017 results from the National Health Interview Survey (NHIS).
A four-stage system that quantifies the extent of cardiac changes associated with aortic stenosis was linked to the odds of death and readmission following transcatheter aortic valve replacement (TAVR), a finding that may aid cardiologists in making prognoses and engaging in shared decision-making with patients.
A contract dispute between Chattanooga, Tennessee-based Erlanger Health System and Tennessee Interventional and Imaging Associates (TIAA) is threatening to upend the hospital’s premiere stroke program, according to documents obtained by the Times Free Press.
The FDA announced Feb. 6 it has approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder.
Hospitals participating in the second phase of a quality improvement program through the American Heart Association/American Stroke Association reduced their median door-to-needle times for acute ischemic stroke patients from 66 minutes to 51 minutes. And the program is now setting its goals even higher.
DUBLIN — February 7, 2019 — Medtronic plc (NYSE:MDT) announced today that it has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex embolization device.
